BRAF and melanoma: Wang et al. demonstrated that IRF9-STAT2 signaling enhances adaptive resistance to BRAF inhibitors (BRAFis) in melanoma cells by regulating GSDME-mediated pyroptosis, thereby elucidating the pathogenesis of resistance in targeted therapy [99].